Legal status · United States
Is Bradykinin legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Bradykinin is not an approved medicine in the United States; its classification is "Not approved; research use only". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Bradykinin in the United States at a glance
| Classification | Not approved; research use only |
|---|---|
| Note | There is no bradykinin medicinal product. It is used as a research reagent and as a provocation agent in physiology studies conducted under research protocols. |
| FDA approval status | Not an approved drug. Bradykinin is an endogenous mediator and a laboratory reagent; no bradykinin product appeared in the Drugs@FDA checks run for this batch. The approved medicine acting on this system is the B2 receptor antagonist icatibant. |
| Human studies cited | 4 of 6 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Bradykinin profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
No product containing Bradykinin is approved by FDA for any use in the United States, so nothing on the market is authorized for people.
- 02
"Research use only" is a vendor label, not a legal category that permits human use. It does not exempt a product from medicines law.
- 03
Importing, supplying or promoting it for human use can fall under medicines legislation in the United States. This page is general information, not legal advice.
What Bradykinin is
A 9 amino acid inflammatory mediator, not a therapy. It is the reason ACE inhibitors cause cough and angioedema, and human forearm and nerve studies have measured what it does; there is no clinical use for administering it.
Bradykinin is a 9 amino acid peptide, sequence RPPGFSPFR, released from kininogen by kallikrein enzymes during inflammation and tissue injury. It dilates blood vessels, increases vascular permeability and sensitises pain-carrying nerves.
Mechanism: In humans, bradykinin acts at two G protein-coupled receptors: B2, which is present constitutively, and B1, which is induced by inflammation. B2 activation on endothelium releases nitric oxide and prostacyclin, producing vasodilation and increased permeability; on nociceptors it lowers the threshold for firing.
Regulatory history: Not an approved drug. Bradykinin is an endogenous mediator and a laboratory reagent; no bradykinin product appeared in the Drugs@FDA checks run for this batch. The approved medicine acting on this system is the B2 receptor antagonist icatibant.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Bradykinin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Bradykinin in other countries
Frequently asked questions
Is Bradykinin legal in the United States?
No. Bradykinin is not an approved medicine in the United States; its classification is "Not approved; research use only". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 4 human studies are cited on its profile. Note: There is no bradykinin medicinal product. It is used as a research reagent and as a provocation agent in physiology studies conducted under research protocols.
Can I buy Bradykinin in the United States?
No approved product exists to buy. In the United States Bradykinin is classified as "Not approved; research use only", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: There is no bradykinin medicinal product. It is used as a research reagent and as a provocation agent in physiology studies conducted under research protocols.
Is Bradykinin FDA approved?
No. FDA status: Not an approved drug. Bradykinin is an endogenous mediator and a laboratory reagent; no bradykinin product appeared in the Drugs@FDA checks run for this batch. The approved medicine acting on this system is the B2 receptor antagonist icatibant.. Current US classification: "Not approved; research use only". On the evidence, 4 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Bradykinin live on its compound profile.
Bradykinin profileThis page is general information about the regulatory status of Bradykinin in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.